IFN-α and IFN-β inhibit NLRP1-driven PANoptosis.
- 1 cites
Type I interferons inhibit NLRP1-driven PANoptosis by reducing NLRP1 expression through a TLR4-TRIF-IRF3 signaling pathway.
- Why it matters: Understanding how innate immune responses are regulated is crucial for developing therapies for inflammatory diseases linked to NLRP1 mutations, which can cause excessive cell death and inflammation.
- What they did: The study examined the effects of LPS and type I IFNs on NLRP1 activation using mouse and human macrophages, demonstrating that these signals suppress NLRP1-driven cell death by downregulating NLRP1 expression.
- The result: This work reveals that type I IFNs serve as negative regulators of NLRP1-mediated inflammation, highlighting their potential as therapeutic agents for NLRP1-related inflammatory conditions.